Literature DB >> 11231045

A molecular modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2.

P Bernard1, M Pintore, J Y Berthon, J R Chrétien.   

Abstract

Automated docking allowing protein-based alignment was performed for a series of 188 indole inhibitors of the human non-pancreatic secretory phospholipase A2 (hnps-PLA2). All the substituted indoles were docked to the crystal structure of hnps-PLA2 and a three-dimensional QSAR model was then established using the CoMFA method. The set of 188 compounds was divided into two subsets, the first one constituting the training set (126 compounds), while the second constituted the test set (62 compounds). The established CoMFA model derived from the training set was then applied to the test set. A good correlation between predicted and experimental activity data allows to validate the 3D QSAR model. A second and global 3D QSAR including all the compounds was established, allowing the creation of the hnps-PLA2 pharmacophore.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11231045     DOI: 10.1016/s0223-5234(00)01183-1

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection.

Authors:  Alexander Golbraikh; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

2.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection.

Authors:  Alexander Golbraikh; Alexander Tropsha
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

3.  Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors.

Authors:  Preethi Badrinarayan; P Srivani; G Narahari Sastry
Journal:  J Mol Model       Date:  2010-06-23       Impact factor: 1.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.